Pelthos Therapeutics Inc. - 10-Q Filing
Pelthos Therapeutics reports Q3 2026 results featuring significant customer concentration and complex debt structures involving Series A/C preferred stock.
Tickers: $PTHS
Pelthos Therapeutics reports Q3 2026 results featuring significant customer concentration and complex debt structures involving Series A/C preferred stock.
Tickers: $PTHS